Review
Biological Threats and Terrorism: Assessing The Science and Response Capabilities
Washington (DC): National Academies Press (US); 2002.
- PMID: 22787686
- Bookshelf ID: NBK98408
- DOI: 10.17226/10290
Item in Clipboard
Review
Biological Threats and Terrorism: Assessing The Science and Response Capabilities
Excerpt
In the wake of September 11 and recent anthrax events, our nation's bioterrorism response capability has become an imminent priority for policymakers, researchers, public health officials, academia, and the private sector. Experts from each of these communities and the Forum on Emerging Infections convened for a three-day workshop discussion—the subject of this summary—to identify, clarify, and prioritize the next steps that need to be taken in order to prepare and strengthen bioterrorism response capabilities.
Copyright © 2002, National Academy of Sciences.
Sections
- THE NATIONAL ACADEMIES
- FORUM ON EMERGING INFECTIONS
- BOARD ON GLOBAL HEALTH
- REVIEWERS
- Preface
- Summary and Assessment
- 1. Introduction
- 2. Assessing Our Understanding of the Threats
- 3. Vaccines: Research, Development, Production, and Procurement Issues
- 4. The Research Agenda: Implications for Therapeutic Countermeasures to Biological Threats
- 5. Assessing the Capacity of the Public Health Infrastructure
- 6. Scientific and Policy Tools for Countering Bioterrorism
- APPENDIXES
Publication types
Grants and funding
Support for this project was provided by the U.S. Department of Health and Human Services' National Institutes of Health, Centers for Disease Control and Prevention, the U.S. Agency for International Development, and the U.S. Food and Drug Administration; U.S. Department of Defense; U.S. Department of State; U.S. Department of Veterans Affairs; U.S. Department of Agriculture; American Society for Microbiology; Bristol-Myers Squibb Company; Burroughs Wellcome Fund; Eli Lilly & Company; Pfizer; GlaxoSmithKline; and Wyeth-Ayerst Laboratories.
LinkOut - more resources
Full Text Sources
